Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma

Leukemia and Lymphoma

Volumn 46, Issue 11, 2005, Pages 1569-1573

  Vose, Julie M ^a   Link, B K ^b   Grossbard, M L ^c   Czuczman, M ^d   Grillo Lopez, A ^e   Fisher, R I ^f  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e Neoplastic and Autoimmune Disease Research Institute   (United States)

^f UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Diffuse large B cell lymphoma; Non Hodgkin's lymphoma

Indexed keywords

CD20 ANTIBODY; CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; DOXORUBICIN; PARACETAMOL; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; BLOOD TOXICITY; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; CHIMERA; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG EXPOSURE; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; INJECTION SITE REACTION; LONG TERM CARE; LUNG SMALL CELL CANCER; MALE; NEUROTOXICITY; NONHODGKIN LYMPHOMA; NOSE CONGESTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL RATE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAUSE OF DEATH; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PREDNISONE; REMISSION INDUCTION; SURVIVAL ANALYSIS; VINCRISTINE;

EID: 28244439191     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190500217312     Document Type: Article

References (13)

1. Elias L, Portlock CS, Rosenberg SA. Combination chemotherapy of diffuse histiocytic lymphoma with cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP). Cancer 1978;42:1705-1710.
2. Fisher RI, Miller TP, Dana BW, Jones SE, Coltman CA, Dahlberg S et al. Southwest Oncology Group clinical trials for intermediate and high-grade non-Hodgkin's lymphoma. Semin Hematol 1987;24:21-25.
3. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;324: 1002-1006.
4. Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rube C et al. Two weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of DSHNHL. Blood 2004;104:634-641.
5. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83: 435-445.
6. Demiden A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes aB cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997;12:177-186.
7. Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998;92: 1927-1932.
8. Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Gilman P et al. Phase II study of Rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001;19:389-397.
9. The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer 1982;49:2112-2135.
10. Kaplan El, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
11. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002;346: 235-282.
12. Habermann TM, Weller EA, Morrison VA, Cassileth PA, Cohn JB, Dakhil SR et al. Phase III trial of rituximab-CHOP (R-CHOP) versus CHOP with a second randomization to maintenance rituximab (MR) or observation in patients 60 years of age and older with diffuse large B-cell lymphoma (DLBCL). Blood 2003;102:8.
13. Pfreundschuh MG, Trumper L, Ma D, Österborg A, Pettengell R, Trneny M et al. Randomized intergroup trial of first line treatment for patients < 60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab early stopping after the first interim analysis. Proc ASCO 2004;23:6500a.